(Q33808512)

29 July 2017

1 reference

title

Parenteral iron use in the management of anemia in end-stage renal disease patients (English)

1 reference

29 July 2017

1 reference

G R Bailie

1

1 reference

29 July 2017

C A Johnson

series ordinal

2

1 reference

29 July 2017

N A Mason

series ordinal

3

1 reference

29 July 2017

publication date

1 January 2000

1 reference

American Journal of Kidney Diseases

29 July 2017

published in

1 reference

29 July 2017

volume

35

1 reference

29 July 2017

issue

1

1 reference

29 July 2017

page(s)

1-12

1 reference

Sodium ferric gluconate complex in sucrose is safe and effective in hemodialysis patients: North American Clinical Trial

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2800%2970294-0

7 January 2021

A randomized trial of three iron dextran infusion methods for anemia in EPO-treated dialysis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2800%2970294-0

7 January 2021

Iron utilization after iron dextran administration for iron deficiency in patients with dialysis-associated anemia: a prospective analysis and comparison of two agents

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2800%2970294-0

7 January 2021

A randomized controlled study of iron supplementation in patients treated with erythropoietin

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2800%2970294-0

7 January 2021

Intravenous infusion of total dose iron in peritoneal dialysis patients: a critical appraisal

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2800%2970294-0

7 January 2021

Safety aspects of parenteral iron in patients with end-stage renal disease

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2800%2970294-0

7 January 2021

Erythropoietin and iron use in peritoneal dialysis patients. Report from the 1997 HCFA end-stage renal disease core indicators project

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2800%2970294-0

7 January 2021

The safety of intravenous iron dextran in hemodialysis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2800%2970294-0

7 January 2021

Dextran hypersensitivity

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2800%2970294-0

7 January 2021

Safe administration of iron dextran to a patient who reacted to the test dose

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2800%2970294-0

7 January 2021

Successful prevention of an anaphylactoid reaction to iron dextran

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2800%2970294-0

7 January 2021

Value of methylprednisolone in prevention of the arthralgia-myalgia syndrome associated with the total dose infusion of iron dextran: a double blind randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2800%2970294-0

7 January 2021

The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2800%2970294-0

7 January 2021

Iron treatment: impact of safety issues

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2800%2970294-0

7 January 2021

Randomized cross-over study of adverse reactions and cost implications of intravenous push compared with infusion of iron dextran in hemodialysis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2800%2970294-0

7 January 2021

Intravenous iron supplementation for the treatment of the anemia of moderate to severe chronic renal failure patients not receiving dialysis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2800%2970294-0

7 January 2021

Intravenous ferric saccharate as an iron supplement in dialysis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2800%2970294-0

7 January 2021

Mathematical approach for estimating iron needs in hemodialysis patients on erythropoietin therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2800%2970294-0

7 January 2021

Intravenous iron-sucrose complex to reduce epoetin demand in dialysis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2800%2970294-0

7 January 2021

Serious adverse reactions after intravenous ferric gluconate

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2800%2970294-0

7 January 2021

Intravenous Fe-gluconate-Na for iron-deficient patients on hemodialysis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2800%2970294-0

7 January 2021

Regular low-dose intravenous iron therapy improves response to erythropoietin in haemodialysis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2800%2970294-0

7 January 2021

Effectiveness of intravenous administration of Fe-gluconate-Na complex to maintain adequate body iron stores in hemodialysis patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2800%2970294-0

7 January 2021

Iron deficiency in maintenance hemodialysis patients: assessment of diagnosis criteria and of three different iron treatments

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2800%2970294-0

7 January 2021

Systemic reactions to intravenous iron therapy in patients receiving angiotensin converting enzyme inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2800%2970294-0

7 January 2021

'Oversaturation' of transferrin after intravenous ferric gluconate (Ferrlecit(R)) in haemodialysis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2800%2970294-0

7 January 2021

Sodium ferric gluconate complex in sucrose: safer intravenous iron therapy than iron dextrans

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2800%2970294-0

7 January 2021

Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2800%2970294-0

7 January 2021

Effect of an intravenous iron dextran regimen on iron stores, hemoglobin, and erythropoietin requirements in hemodialysis patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2800%2970294-0

7 January 2021

10.1016/S0272-6386(00)70294-0

Identifiers

DOI

1 reference

29 July 2017

1 reference